1,036 results on '"Forconi, Francesco"'
Search Results
52. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model
53. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features
54. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
55. Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
56. DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1
57. EMT-like Activation in CLL Provides Novel Therapeutic Target
58. Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia
59. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK
60. Correction: Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications
61. Development of a distributed international patient data registry for hairy cell leukemia
62. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells
63. KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity
64. CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
65. Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies
66. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
67. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function
68. TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study
69. B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells
70. Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL
71. Biological and clinical insight from analysis of the tumor B-cell 2 receptor structure and function in chronic lymphocytic Leukemia
72. S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis
73. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
74. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
75. B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells
76. Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia
77. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
78. The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma
79. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
80. Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E
81. Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E
82. Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
83. Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance
84. Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial
85. Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior
86. The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome
87. The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity
88. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia
89. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia
90. The normal IGHV1-69–derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL
91. Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells
92. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior
93. Exploring the pathways to chronic lymphocytic leukemia
94. B-cell chronic lymphocytic leukemia
95. Time for a new prognostic score in CLL?
96. Guideline for diagnosis and management of Hairy Cell Leukaemia (HCL) and Hairy Cell Variant (HCL-V) a British Society for Haematology Guideline
97. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma
98. Neutropenia Analysis of Venetoclax Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Pooled Data from VENICE-I and -II Phase 3b Trials
99. Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis
100. Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.